Latest AtaiBeckley News & Updates

See the latest news and media coverage for AtaiBeckley. We track all announcements, press releases, and industry mentions in real time, all in one place.

AtaiBeckley

Mental health biotech company

ataibeckley.com

Headquarters: New York, United States
Company type: Public company
Number of employees: 100–200

Last updated Today

Latest news about AtaiBeckley

In short: AtaiBeckley joined major Russell and S&P indices, reported positive Phase 2 clinical data, and advanced its Phase 3 mental health program.

Company announcements

June 25 AtaiBeckley

AtaiBeckley joins Russell 2000 and 3000 indexes

The addition effective June 29 broadens investor exposure as Phase 3 study advances.

April 22 AtaiBeckley

AtaiBeckley announces additional Phase 2a results for EMP-01

The trial demonstrated clinically meaningful reductions in SAD symptoms and high responder rates with no serious adverse events.

April 8 AtaiBeckley

AtaiBeckley's BPL-003 shows rapid antidepressant response in Phase 2a trial

The drug achieved 66.7% response rate by Day 2 and durable effects through Week 12, with FDA Breakthrough Therapy designation and Phase 3 initiation on track for Q2 2026.

March 17 AtaiBeckley

AtaiBeckley published Phase 2a data showing rapid antidepressant effects

Cohort 1 demonstrated a mean 12.6-point MADRS reduction by Day 2, sustained over 12 weeks, with good tolerability and no serious adverse events.

Media coverage

July 2 Yahoo Finance

AtaiBeckley Stock Outlook Depends on Key Pipeline Catalysts in 2026

ATAI enters a catalyst-heavy 2026 as BPL-003 advances toward phase III, with upcoming pipeline milestones set to shape the ...

June 25 Yahoo Finance

AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution

AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) announced on Thursday that it will be added to the Russell 2000 Index and the Russell 3000 Index, effective at the...

May 12 Nasdaq

AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update

Phase 3 pivotal program initiation for BPL-003 in treatment-resistant depression on track for Q2 2026 VLS-01 Phase 2 Elumina topline results anticipated in Q4 2026...

April 21 Nasdaq

AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- AtaiBeckley Inc. (NASDAQ: ATAI) ("AtaiBeckley" or the "Company"), a clinical‑stage biotechnology company on a mission to transform...

Never miss news about AtaiBeckley

Track AtaiBeckley and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.